<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040584</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001HES01</org_study_id>
    <secondary_id>2013-001191-38</secondary_id>
    <nct_id>NCT02040584</nct_id>
  </id_info>
  <brief_title>A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.</brief_title>
  <acronym>REDUCE</acronym>
  <official_title>A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients. The REDUCE Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assuming greater efficacy in the prevention of acute rejection in the EVR arm with
      minimisation of TAC levels, the hypothesis of the present trial was that the introduction of
      EVR in combination with the minimisation of TAC (rTAC) may offer improved kidney function
      compared with standard therapy with TAC-MMF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicentre, randomized, open-label, controlled, exploratory clinical trial with 12-months
      (52 weeks) of follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2013</start_date>
  <completion_date type="Actual">February 10, 2016</completion_date>
  <primary_completion_date type="Actual">February 10, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multicentre, randomized, open-label, controlled, exploratory clinical trial with 12-months (52 weeks) of follow-up&quot;.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Participants Showing Clinical Benefit by Renal Function Stratification</measure>
    <time_frame>week 4, week 52.</time_frame>
    <description>Clinical benefit is defined as: • an improvement in 1 or 2 ranges of the eGFR, according to MDRD-4 at Week 52 post-transplant in patients with values of 30-&lt;45 or 45-&lt;60 mL/min/1.73 m2 in Week 4. or • stabilisation of eGFR in patients with values ≥60 mL/min/1.73 m2 at Week 4 and maintained at Week 52 post-transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Creatinine Clearance - Cockcroft-Gault Formula</measure>
    <time_frame>Screening visit (transplant), weeks 1,4,12,24,36 and 52 post-transplant</time_frame>
    <description>Kidney function was assessed over time by creatine clearance based on the Cockcroft-Gault formula.
Estimated creatinine clearance (mL/min) = [(140 - age) x (weight) x (0.85 if female)] / (72 x serum creatinine).
Units: age (years); weight (kg); serum creatinine (mg/dL). The values of the eGFR according to the creatinine clearance (Cockcroft-Gault formula) for the ITT population were ml/min/1.73 m^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in eGFR Based on the MDRD-4 Formula</measure>
    <time_frame>Screening visit (transplant), weeks 1,4,12,24,36 and 52 post-transplant</time_frame>
    <description>Kidney function was assessed over time by changes in eGFR according to the MDRD-4 formula. The MDRD-4 formula (Levey et al., 2000) was used based on serum concentration of creatinine (conventional units): eGFR (mL/min/1.73 m2) = 186 x (serum creatinine)-1.154 x (age)-0.203 x (0.742 if female) x (1.210 if of African descent).
Units: serum creatinine (mg/dL); age (years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR Values(MDRD-4 Formula) According to the MELD Score</measure>
    <time_frame>Screening visit (transplant), weeks 1,4,12,24,36 and 52 post-transplant</time_frame>
    <description>Model for End Stage Liver Disease (MELD) score: ≤14, 15-19, 20-24, 25-29, ≥30. The higher the number indicates the urgency for transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Protein/Creatinine Ratio</measure>
    <time_frame>Screening visit, week 1,4,18,24, and 52</time_frame>
    <description>The urine protein/creatinine ratio was assessed throughout follow-up in both treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Incidence of Proteinuria</measure>
    <time_frame>Screening visit, week 1,4,18,24, and 52</time_frame>
    <description>The incidence of proteinuria (≥0.5-0.9 g/day, ≥1.0-2.9 g/day and ≥3.0 g/day) was assessed throughout follow-up in both treatment groups. Proteinuria was defined as protein/creatinine ratio ≥ 0.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Acute Rejection, BPAR, and Treated BPAR</measure>
    <time_frame>Throughout the study period, approximately 2 years and 2 months</time_frame>
    <description>Liver biopsy had to be performed in all cases where acute rejection was suspected. Results of the biopsy were interpreted by the local pathologist (who did not known the treatment given to the patient) according to the Banff classification (1997).
Biopsy-proven acute rejection (BPAR) defined as clinical suspicion of acute rejection confirmed in biopsy.
Treated BPAR was deemed to be an episode of acute rejection in which the interpretation of the local pathologist showed that it reached any grade of acute rejection under the Banff classification, and for which anti-rejection therapy was administered.
Loss of the liver allograft was deemed to have occurred the day that the patient was again included on the waiting list for liver transplant, the day he or she received another allograft or upon the death of the patient.
All suspected hepatic allograft rejections were considered acute rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Rejection</measure>
    <time_frame>Throughout study period, approximately 2 years and 2 months</time_frame>
    <description>Time to acute rejection was calculated from the date of transplantation. Acute rejection date was taken from biopsy date, as the date of rejection was not collected.
Time to treated BPAR was calculated from the date of transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Rejection</measure>
    <time_frame>Throughout study period, approximately 2 years and 2 months</time_frame>
    <description>Severity of acute rejection and treated BPAR was graded according to Banff criteria.
Grade of acute rejection according to Banff criteria: mild, moderate, severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Participants With HCV-positive and HCV Genotype</measure>
    <time_frame>approximately 2 years and 2 months</time_frame>
    <description>The viral load of HCV-RNA and HCV genotype was assessed in HCV-positive patients.
The term &quot;genotype&quot; was used to describe strains of HCV that vary but were related to the virus. Worldwide, there were 11 primary groups of HCV genotypes designated by the numbers from 1-11, with the most common in our setting being subtypes 1a, 1b, 2 and 3, which were identified in the local laboratory according to their usual testing methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of p-P70S6K</measure>
    <time_frame>weeks 6,8,12,18,24,36,52 at 0 (Cmin), and 1 (C1h) hrs post-dose.</time_frame>
    <description>the biomarker of personal response to everolimus, monitoring of the activity of the target, kinase P70 S6, in its phosphorylated form at Thr389.
EVR=everolimus Cmin=minimum concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">217</enrollment>
  <condition>Liver Transplant</condition>
  <arm_group>
    <arm_group_label>Minimisation of TAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with rTAC+EVR+corticosteroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAC + MMF + corticosteroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with TAC + MMF + corticosteroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minimisation of TAC</intervention_name>
    <description>•EVR: Treatment started at a total daily dose of 2 mg within 24 hours after randomisation. The dose of EVR was adjusted upon reaching trough levels (C-0h) in whole blood of 3-8 ng/mL. The daily dose (in two administrations) of EVR may have been modified to maintain trough levels (C-0h) in whole blood of 3-8 ng/mL until Week 52 post-transplant. •TAC: Once confirmation was obtained, beginning in Week 5, that trough levels (C-0h) in whole blood of EVR were between 3-8 ng/mL, minimisation of TAC began, in order to reach trough levels (C-0h) of TAC in whole blood of ≤5 ng/mL no later than four weeks after randomisation (Week 8), which were levels that should have been maintained until Week 52 post-transplant. •MMF was withdrawn at the same time that EVR was introduced. •oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted</description>
    <arm_group_label>Minimisation of TAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAC + MMF + corticosteroids</intervention_name>
    <description>•Dose of TAC: Trough levels (C-0h) of TAC in whole blood should have been maintained between 6-10 ng/mL until Week 52 post-transplant. •Dose of MMF: Doses of 500-1000 mg/12 hrs was maintained until Week 52. •Corticosteroids: During the study, oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted (e.g. in patients with a history of HCV). It was recommended in any case that corticosteroids not be administered beyond Week 24 post-transplant except in cases of hepatopathy of autoimmune origin. At each centre all patients should have followed the same administration protocol for corticosteroids based on history of HCV.</description>
    <arm_group_label>TAC + MMF + corticosteroids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Screening Visit - Inclusion Criteria

          1. Recipients age 18 or over receiving a first liver transplant from a cadaver donor.

          2. Patients diagnosed with HCC must meet the Milan radiological criteria at the time of
             transplant (1 nodule ≤5 cm in diameter, or 2-3 nodules, all &lt;3 cm in diameter) - at
             time of patient's inclusion on the waiting list.

             Anh: done.

          3. Patients who have signed the informed consent to participate in the study.

          4. Patients who by medical criteria are capable of complying with the study regimen.

        Screening Visit - Exclusion Criteria

          1. Recipients who have received multiple transplants of solid organs or pancreatic islet
             cells.

          2. Patients who have previously received an organ or tissue transplant.

          3. Patients with a combined liver-kidney transplant.

          4. Recipients of lobes or segments of liver from a live donor.

          5. A history of malignancy of any organ system in the previous 3 years according to local
             protocols (regardless of signs of local recurrence or metastasis), other than
             non-metastasising basal cell carcinoma or squamous cell carcinoma (epidermoid
             carcinoma) of the skin, or HCC.

          6. Patients with known hypersensitivity to the drugs used in the study or others of their
             class, or to any of their excipients.

          7. Recipients of ABO-incompatible transplants.

          8. Patients who test positive for HIV.

          9. Recipients of organs from donors who tested positive for the hepatitis B surface
             antigen or HIV seropositive.

         10. Patients with any medical or surgical condition that in the opinion of the
             investigator may significantly alter the absorption, distribution, metabolism or
             excretion of the study medication.

         11. Women of childbearing potential (i.e. women who are not postmenopausal with
             amenorrhoea of more than 1 year or surgically sterile) who are planning to become
             pregnant, are pregnant and/or breastfeeding, or who do not wish to use effective
             contraception, e.g. hormonal contraceptives (implantation, patches, oral) and
             double-barrier methods (any double combination of: IUD, male or female condoms with
             spermicidal gel, diaphragm, contraceptive sponge, cervical cap).

         12. Patients who are taking part in another clinical trial.

        Randomisation Visit - Inclusion Criteria

          1. Functioning allograft at the time of randomisation. A functioning allograft is defined
             as:

               1. levels of AST, ALT and total bilirubin ≤ 4 times the upper limit of normal, and

               2. levels of alkaline phosphatase and GGT ≤ 5 times the upper limit of normal.

          2. Glomerular filtrate ≥30 mL/min/1.73 m2 (calculated using the MDRD-4 equation).

        Randomisation Visit - Exclusion Criteria

          1. Patients with proteinuria ≥1.0 g/24 hrs confirmed in the urine sample
             (protein/creatinine ratio) that cannot be explained by immediate post-operative
             causes.

          2. Patients with severe hypercholesterolaemia (≥350 mg/dL; ≥9 mmol/L) or severe
             hypertriglyceridaemia (≥750 mg/dL; ≥8.5 mmol/L).

          3. Patients with a platelet count ≤50,000/mm3.

          4. Patients with an absolute neutrophil count ≤1,000/mm3 or WBC count ≤2,000/mm3.

          5. Patients who cannot take oral medication.

          6. Patients with clinically significant systemic infection who require active use of
             intravenous antibiotics.

          7. Patients who are in intensive care units and require vital support measures such as
             mechanical ventilation, dialysis, or vasoactive drugs.

          8. Patients who have required renal replacement therapy in the 7 days prior to
             randomisation.

          9. Patients who have had an episode of acute rejection and have required antibody therapy
             or who have had more than one episode of corticosteroid-sensitive acute rejection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucia</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valladolid</city>
        <state>Castilla Y Leon</state>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Cataluña</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barakaldo</city>
        <state>Pais Vasco</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <results_first_submitted>March 7, 2018</results_first_submitted>
  <results_first_submitted_qc>March 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 13, 2019</results_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>De Novo Liver Transplant, Tacrolimus Minimisation, Everolimus, Renal Function, Liver transplant, allograft rejection, xenograft rejection, host vs graft disease</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients enrolled were 217, patients in the safety population were 215, and patients in the ITT population were 211.</recruitment_details>
      <pre_assignment_details>The intention-to-treat population (ITT) that was used for all efficacy analyses included all randomised patients who had received at least one dose of the study medication (safety population) and had at least one assessment subsequent to the randomisation visit for determining the primary efficacy endpoint.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental Group</title>
          <description>Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Treatment with TAC + MMF + corticosteroids</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transplant rejection/retransplant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Immunosuppressant/prohibited med use</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat (ITT) population included all randomised patients who had received at least one dose of the study medication and had at least one assessment subsequent to the randomization visit for determining the primary efficacy endpoint. Patients were analysed according to the treatment to which they were assigned at randomisation.</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental Group</title>
          <description>Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Treatment with TAC + MMF + corticosteroids</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="106"/>
            <count group_id="B3" value="211"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.43" spread="6.37"/>
                    <measurement group_id="B2" value="55.84" spread="7.45"/>
                    <measurement group_id="B3" value="57.13" spread="7.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Participants Showing Clinical Benefit by Renal Function Stratification</title>
        <description>Clinical benefit is defined as: • an improvement in 1 or 2 ranges of the eGFR, according to MDRD-4 at Week 52 post-transplant in patients with values of 30-&lt;45 or 45-&lt;60 mL/min/1.73 m2 in Week 4. or • stabilisation of eGFR in patients with values ≥60 mL/min/1.73 m2 at Week 4 and maintained at Week 52 post-transplant.</description>
        <time_frame>week 4, week 52.</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Treatment with TAC + MMF + corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Participants Showing Clinical Benefit by Renal Function Stratification</title>
          <description>Clinical benefit is defined as: • an improvement in 1 or 2 ranges of the eGFR, according to MDRD-4 at Week 52 post-transplant in patients with values of 30-&lt;45 or 45-&lt;60 mL/min/1.73 m2 in Week 4. or • stabilisation of eGFR in patients with values ≥60 mL/min/1.73 m2 at Week 4 and maintained at Week 52 post-transplant.</description>
          <population>ITT</population>
          <units>Percentages of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt; = 30 - 45 ml/min/1.73m^2 at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76"/>
                    <measurement group_id="O2" value="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; = 45 - &lt;60 ml/min/1.73m^2 at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.29"/>
                    <measurement group_id="O2" value="16.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; = 60 ml/min/1.73m^2 at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.05"/>
                    <measurement group_id="O2" value="79.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis (H0): there were no differences in kidney function between the two groups, in contrast with the alternative hypothesis (H1), in which there were differences:
HO: CBS = CBC versus H1: CBS ≠ CBC, where CBS and CBC were percentages of patients who showed clinical benefit at Week 52 for the study group and control group, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9423</p_value>
            <method>Fisher Exact</method>
            <method_desc>Week 52</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Creatinine Clearance - Cockcroft-Gault Formula</title>
        <description>Kidney function was assessed over time by creatine clearance based on the Cockcroft-Gault formula.
Estimated creatinine clearance (mL/min) = [(140 - age) x (weight) x (0.85 if female)] / (72 x serum creatinine).
Units: age (years); weight (kg); serum creatinine (mg/dL). The values of the eGFR according to the creatinine clearance (Cockcroft-Gault formula) for the ITT population were ml/min/1.73 m^2.</description>
        <time_frame>Screening visit (transplant), weeks 1,4,12,24,36 and 52 post-transplant</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Treatment with TAC + MMF + corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Creatinine Clearance - Cockcroft-Gault Formula</title>
          <description>Kidney function was assessed over time by creatine clearance based on the Cockcroft-Gault formula.
Estimated creatinine clearance (mL/min) = [(140 - age) x (weight) x (0.85 if female)] / (72 x serum creatinine).
Units: age (years); weight (kg); serum creatinine (mg/dL). The values of the eGFR according to the creatinine clearance (Cockcroft-Gault formula) for the ITT population were ml/min/1.73 m^2.</description>
          <population>ITT</population>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.67" spread="36.40"/>
                    <measurement group_id="O2" value="109.69" spread="48.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.93" spread="44.82"/>
                    <measurement group_id="O2" value="118.09" spread="44.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.19" spread="28.00"/>
                    <measurement group_id="O2" value="91.26" spread="37.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.76" spread="26.51"/>
                    <measurement group_id="O2" value="90.14" spread="35.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.57" spread="32.89"/>
                    <measurement group_id="O2" value="87.93" spread="35.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.46" spread="30.26"/>
                    <measurement group_id="O2" value="90.91" spread="35.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.21" spread="29.96"/>
                    <measurement group_id="O2" value="91.04" spread="37.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in eGFR Based on the MDRD-4 Formula</title>
        <description>Kidney function was assessed over time by changes in eGFR according to the MDRD-4 formula. The MDRD-4 formula (Levey et al., 2000) was used based on serum concentration of creatinine (conventional units): eGFR (mL/min/1.73 m2) = 186 x (serum creatinine)-1.154 x (age)-0.203 x (0.742 if female) x (1.210 if of African descent).
Units: serum creatinine (mg/dL); age (years).</description>
        <time_frame>Screening visit (transplant), weeks 1,4,12,24,36 and 52 post-transplant</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Treatment with TAC + MMF + corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in eGFR Based on the MDRD-4 Formula</title>
          <description>Kidney function was assessed over time by changes in eGFR according to the MDRD-4 formula. The MDRD-4 formula (Levey et al., 2000) was used based on serum concentration of creatinine (conventional units): eGFR (mL/min/1.73 m2) = 186 x (serum creatinine)-1.154 x (age)-0.203 x (0.742 if female) x (1.210 if of African descent).
Units: serum creatinine (mg/dL); age (years).</description>
          <population>ITT</population>
          <units>ml/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.20" spread="38.74"/>
                    <measurement group_id="O2" value="99.42" spread="43.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.86" spread="50.06"/>
                    <measurement group_id="O2" value="112.15" spread="48.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.18" spread="28.47"/>
                    <measurement group_id="O2" value="88.39" spread="34.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.99" spread="25.13"/>
                    <measurement group_id="O2" value="83.57" spread="28.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.02" spread="31.97"/>
                    <measurement group_id="O2" value="82.00" spread="26.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.68" spread="32.49"/>
                    <measurement group_id="O2" value="83.04" spread="25.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.09" spread="27.87"/>
                    <measurement group_id="O2" value="83.23" spread="25.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>eGFR Values(MDRD-4 Formula) According to the MELD Score</title>
        <description>Model for End Stage Liver Disease (MELD) score: ≤14, 15-19, 20-24, 25-29, ≥30. The higher the number indicates the urgency for transplant.</description>
        <time_frame>Screening visit (transplant), weeks 1,4,12,24,36 and 52 post-transplant</time_frame>
        <population>ITT population (patients with MDRD-4 values).</population>
        <group_list>
          <group group_id="O1">
            <title>&lt;= 14</title>
            <description>Experimental group (Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids) with MELD score &lt;= 14</description>
          </group>
          <group group_id="O2">
            <title>15 to 19</title>
            <description>Experimental group (Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids) with MELD score 15-19</description>
          </group>
          <group group_id="O3">
            <title>20 to 24</title>
            <description>Experimental group (Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids) with MELD score 20 to 24</description>
          </group>
          <group group_id="O4">
            <title>25 to 29</title>
            <description>Experimental group (Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids) with MELD score 25 to 29</description>
          </group>
          <group group_id="O5">
            <title>&gt; = 30</title>
            <description>Experimental group (Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids) with MELD score &gt; = 30</description>
          </group>
          <group group_id="O6">
            <title>&lt;= 14 Control Group</title>
            <description>Control group (Treatment with TAC + MMF + corticosteroids) with MELD score &lt;= 14</description>
          </group>
          <group group_id="O7">
            <title>15 to 19 Control Group</title>
            <description>Control group (Treatment with TAC + MMF + corticosteroids) with MELD score 15 to 19</description>
          </group>
          <group group_id="O8">
            <title>20 to 24 Control Group</title>
            <description>Control group (Treatment with TAC + MMF + corticosteroids) with MELD score 20 to 24</description>
          </group>
          <group group_id="O9">
            <title>25 to 29 Control Group</title>
            <description>Control group (Treatment with TAC + MMF + corticosteroids) with MELD score 25 to 29</description>
          </group>
          <group group_id="O10">
            <title>&gt; = 30 Control Group</title>
            <description>Control group (Treatment with TAC + MMF + corticosteroids) with MELD score &gt; = 30</description>
          </group>
        </group_list>
        <measure>
          <title>eGFR Values(MDRD-4 Formula) According to the MELD Score</title>
          <description>Model for End Stage Liver Disease (MELD) score: ≤14, 15-19, 20-24, 25-29, ≥30. The higher the number indicates the urgency for transplant.</description>
          <population>ITT population (patients with MDRD-4 values).</population>
          <units>ml/min/1.73m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="56"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.63" lower_limit="76.31" upper_limit="119.50"/>
                    <measurement group_id="O2" value="90.29" lower_limit="65.64" upper_limit="114.92"/>
                    <measurement group_id="O3" value="88.89" lower_limit="70.03" upper_limit="114.67"/>
                    <measurement group_id="O4" value="104.45" lower_limit="93.21" upper_limit="123.90"/>
                    <measurement group_id="O5" value="38.35" lower_limit="38.35" upper_limit="38.35"/>
                    <measurement group_id="O6" value="102.27" lower_limit="75.09" upper_limit="120.19"/>
                    <measurement group_id="O7" value="93.85" lower_limit="73.93" upper_limit="123.19"/>
                    <measurement group_id="O8" value="91.45" lower_limit="68.74" upper_limit="116.49"/>
                    <measurement group_id="O9" value="99.50" lower_limit="19.76" upper_limit="137.89"/>
                    <measurement group_id="O10" value="53.73" lower_limit="38.82" upper_limit="66.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.00" lower_limit="94.24" upper_limit="142.51"/>
                    <measurement group_id="O2" value="93.31" lower_limit="76.61" upper_limit="127.75"/>
                    <measurement group_id="O3" value="83.45" lower_limit="66.76" upper_limit="114.06"/>
                    <measurement group_id="O4" value="137.61" lower_limit="124.30" upper_limit="148.67"/>
                    <measurement group_id="O5" value="82.04" lower_limit="82.04" upper_limit="82.04"/>
                    <measurement group_id="O6" value="108.64" lower_limit="83.22" upper_limit="138.55"/>
                    <measurement group_id="O7" value="92.98" lower_limit="55.41" upper_limit="129.49"/>
                    <measurement group_id="O8" value="119.19" lower_limit="100.53" upper_limit="147.60"/>
                    <measurement group_id="O9" value="156.41" lower_limit="29.81" upper_limit="184.87"/>
                    <measurement group_id="O10" value="86.45" lower_limit="57.98" upper_limit="117.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.37" lower_limit="63.46" upper_limit="92.20"/>
                    <measurement group_id="O2" value="85.19" lower_limit="66.09" upper_limit="99.26"/>
                    <measurement group_id="O3" value="70.57" lower_limit="51.90" upper_limit="99.02"/>
                    <measurement group_id="O4" value="75.94" lower_limit="50.93" upper_limit="121.86"/>
                    <measurement group_id="O5" value="69.43" lower_limit="69.43" upper_limit="69.43"/>
                    <measurement group_id="O6" value="89.44" lower_limit="62.78" upper_limit="107.55"/>
                    <measurement group_id="O7" value="72.76" lower_limit="51.64" upper_limit="113.93"/>
                    <measurement group_id="O8" value="89.67" lower_limit="63.89" upper_limit="133.44"/>
                    <measurement group_id="O9" value="85.23" lower_limit="42.83" upper_limit="109.13"/>
                    <measurement group_id="O10" value="78.57" lower_limit="51.47" upper_limit="108.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.81" lower_limit="64.65" upper_limit="98.87"/>
                    <measurement group_id="O2" value="88.76" lower_limit="65.92" upper_limit="118.20"/>
                    <measurement group_id="O3" value="83.91" lower_limit="68.46" upper_limit="94.96"/>
                    <measurement group_id="O4" value="94.82" lower_limit="50.94" upper_limit="106.28"/>
                    <measurement group_id="O5" value="56.67" lower_limit="56.67" upper_limit="56.67"/>
                    <measurement group_id="O6" value="83.63" lower_limit="69.33" upper_limit="101.35"/>
                    <measurement group_id="O7" value="67.00" lower_limit="48.31" upper_limit="99.84"/>
                    <measurement group_id="O8" value="87.22" lower_limit="67.63" upper_limit="107.01"/>
                    <measurement group_id="O9" value="65.01" lower_limit="43.15" upper_limit="96.53"/>
                    <measurement group_id="O10" value="81.92" lower_limit="58.33" upper_limit="87.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.76" lower_limit="64.37" upper_limit="107.89"/>
                    <measurement group_id="O2" value="81.41" lower_limit="57.22" upper_limit="104.86"/>
                    <measurement group_id="O3" value="78.88" lower_limit="62.22" upper_limit="94.68"/>
                    <measurement group_id="O4" value="84.86" lower_limit="68.54" upper_limit="101.19"/>
                    <measurement group_id="O5" value="60.37" lower_limit="60.37" upper_limit="60.37"/>
                    <measurement group_id="O6" value="80.01" lower_limit="66.16" upper_limit="97.47"/>
                    <measurement group_id="O7" value="70.27" lower_limit="55.26" upper_limit="93.99"/>
                    <measurement group_id="O8" value="82.64" lower_limit="65.25" upper_limit="113.80"/>
                    <measurement group_id="O9" value="88.34" lower_limit="30.17" upper_limit="104.72"/>
                    <measurement group_id="O10" value="62.74" lower_limit="47.46" upper_limit="75.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.96" lower_limit="64.82" upper_limit="111.44"/>
                    <measurement group_id="O2" value="92.44" lower_limit="68.05" upper_limit="113.18"/>
                    <measurement group_id="O3" value="75.62" lower_limit="61.64" upper_limit="100.46"/>
                    <measurement group_id="O4" value="83.09" lower_limit="55.72" upper_limit="110.46"/>
                    <measurement group_id="O5" value="58.07" lower_limit="58.07" upper_limit="58.07"/>
                    <measurement group_id="O6" value="86.72" lower_limit="72.09" upper_limit="97.40"/>
                    <measurement group_id="O7" value="67.90" lower_limit="54.34" upper_limit="90.95"/>
                    <measurement group_id="O8" value="86.17" lower_limit="68.59" upper_limit="107.21"/>
                    <measurement group_id="O9" value="68.32" lower_limit="57.01" upper_limit="79.63"/>
                    <measurement group_id="O10" value="65.58" lower_limit="45.11" upper_limit="73.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.14" lower_limit="66.70" upper_limit="101.59"/>
                    <measurement group_id="O2" value="88.94" lower_limit="65.24" upper_limit="114.50"/>
                    <measurement group_id="O3" value="71.60" lower_limit="62.48" upper_limit="89.66"/>
                    <measurement group_id="O4" value="83.94" lower_limit="60.69" upper_limit="107.20"/>
                    <measurement group_id="O5" value="53.93" lower_limit="53.93" upper_limit="53.93"/>
                    <measurement group_id="O6" value="80.92" lower_limit="68.98" upper_limit="104.03"/>
                    <measurement group_id="O7" value="70.32" lower_limit="54.12" upper_limit="82.38"/>
                    <measurement group_id="O8" value="90.66" lower_limit="74.52" upper_limit="113.18"/>
                    <measurement group_id="O9" value="74.82" lower_limit="69.00" upper_limit="80.63"/>
                    <measurement group_id="O10" value="63.26" lower_limit="45.52" upper_limit="79.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Protein/Creatinine Ratio</title>
        <description>The urine protein/creatinine ratio was assessed throughout follow-up in both treatment groups.</description>
        <time_frame>Screening visit, week 1,4,18,24, and 52</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Treatment with TAC + MMF + corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Protein/Creatinine Ratio</title>
          <description>The urine protein/creatinine ratio was assessed throughout follow-up in both treatment groups.</description>
          <population>ITT</population>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.89" spread="582.03"/>
                    <measurement group_id="O2" value="131.56" spread="178.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.48" spread="308.22"/>
                    <measurement group_id="O2" value="349.46" spread="396.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.77" spread="175.05"/>
                    <measurement group_id="O2" value="141.71" spread="187.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204.26" spread="688.05"/>
                    <measurement group_id="O2" value="105.02" spread="79.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.17" spread="466.55"/>
                    <measurement group_id="O2" value="120.52" spread="108.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.41" spread="406.52"/>
                    <measurement group_id="O2" value="143.05" spread="220.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Incidence of Proteinuria</title>
        <description>The incidence of proteinuria (≥0.5-0.9 g/day, ≥1.0-2.9 g/day and ≥3.0 g/day) was assessed throughout follow-up in both treatment groups. Proteinuria was defined as protein/creatinine ratio ≥ 0.5.</description>
        <time_frame>Screening visit, week 1,4,18,24, and 52</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Treatment with TAC + MMF + corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Incidence of Proteinuria</title>
          <description>The incidence of proteinuria (≥0.5-0.9 g/day, ≥1.0-2.9 g/day and ≥3.0 g/day) was assessed throughout follow-up in both treatment groups. Proteinuria was defined as protein/creatinine ratio ≥ 0.5.</description>
          <population>ITT</population>
          <units>Percentages of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 0.5-1.0 g/day at screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1.0-3.0 g/day at screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00"/>
                    <measurement group_id="O2" value="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3.0 g/day at screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5-1.0 g/day at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23"/>
                    <measurement group_id="O2" value="18.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1.0-3.0 g/day at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45"/>
                    <measurement group_id="O2" value="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3.0 g/day at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5-1.0 g/day at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21"/>
                    <measurement group_id="O2" value="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1.0-3.0 g/day at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3.0 g/day at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5-1.0 g/day at Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1.0-3.0 g/day at Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3.0 g/day at Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5-1.0 g/day at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.58"/>
                    <measurement group_id="O2" value="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1.0-3.0 g/day at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3.0 g/day at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5-1.0 g/day at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                    <measurement group_id="O2" value="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1.0-3.0 g/day at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33"/>
                    <measurement group_id="O2" value="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3.0 g/day at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Acute Rejection, BPAR, and Treated BPAR</title>
        <description>Liver biopsy had to be performed in all cases where acute rejection was suspected. Results of the biopsy were interpreted by the local pathologist (who did not known the treatment given to the patient) according to the Banff classification (1997).
Biopsy-proven acute rejection (BPAR) defined as clinical suspicion of acute rejection confirmed in biopsy.
Treated BPAR was deemed to be an episode of acute rejection in which the interpretation of the local pathologist showed that it reached any grade of acute rejection under the Banff classification, and for which anti-rejection therapy was administered.
Loss of the liver allograft was deemed to have occurred the day that the patient was again included on the waiting list for liver transplant, the day he or she received another allograft or upon the death of the patient.
All suspected hepatic allograft rejections were considered acute rejection</description>
        <time_frame>Throughout the study period, approximately 2 years and 2 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Treatment with TAC + MMF + corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Acute Rejection, BPAR, and Treated BPAR</title>
          <description>Liver biopsy had to be performed in all cases where acute rejection was suspected. Results of the biopsy were interpreted by the local pathologist (who did not known the treatment given to the patient) according to the Banff classification (1997).
Biopsy-proven acute rejection (BPAR) defined as clinical suspicion of acute rejection confirmed in biopsy.
Treated BPAR was deemed to be an episode of acute rejection in which the interpretation of the local pathologist showed that it reached any grade of acute rejection under the Banff classification, and for which anti-rejection therapy was administered.
Loss of the liver allograft was deemed to have occurred the day that the patient was again included on the waiting list for liver transplant, the day he or she received another allograft or upon the death of the patient.
All suspected hepatic allograft rejections were considered acute rejection</description>
          <population>ITT</population>
          <units>Percentages of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with suspected acute rejection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.14"/>
                    <measurement group_id="O2" value="15.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with BPAR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71"/>
                    <measurement group_id="O2" value="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with treated BPAR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76"/>
                    <measurement group_id="O2" value="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Rejection</title>
        <description>Time to acute rejection was calculated from the date of transplantation. Acute rejection date was taken from biopsy date, as the date of rejection was not collected.
Time to treated BPAR was calculated from the date of transplantation.</description>
        <time_frame>Throughout study period, approximately 2 years and 2 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Treatment with TAC + MMF + corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Rejection</title>
          <description>Time to acute rejection was calculated from the date of transplantation. Acute rejection date was taken from biopsy date, as the date of rejection was not collected.
Time to treated BPAR was calculated from the date of transplantation.</description>
          <population>ITT</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time to acute rejection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.74" spread="3.15"/>
                    <measurement group_id="O2" value="2.91" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to treated BPAR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" spread="1.50"/>
                    <measurement group_id="O2" value="3.85" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Rejection</title>
        <description>Severity of acute rejection and treated BPAR was graded according to Banff criteria.
Grade of acute rejection according to Banff criteria: mild, moderate, severe.</description>
        <time_frame>Throughout study period, approximately 2 years and 2 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Treatment with TAC + MMF + corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Rejection</title>
          <description>Severity of acute rejection and treated BPAR was graded according to Banff criteria.
Grade of acute rejection according to Banff criteria: mild, moderate, severe.</description>
          <population>ITT</population>
          <units>Percentages of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severity of acute rejection: Mild (Grade I)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.64" spread="3.15"/>
                    <measurement group_id="O2" value="11.11" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of acute rejection: Moderate(Grade II)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.64" spread="1.50"/>
                    <measurement group_id="O2" value="5.56" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of acute rejection: Severe(Grade III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of treated BPAR: Mild (Grade I)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of treated BPAR: Moderate(Grade II)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                    <measurement group_id="O2" value="50.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of treated BPAR: Severe(Grade III)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="50.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Participants With HCV-positive and HCV Genotype</title>
        <description>The viral load of HCV-RNA and HCV genotype was assessed in HCV-positive patients.
The term &quot;genotype&quot; was used to describe strains of HCV that vary but were related to the virus. Worldwide, there were 11 primary groups of HCV genotypes designated by the numbers from 1-11, with the most common in our setting being subtypes 1a, 1b, 2 and 3, which were identified in the local laboratory according to their usual testing methods.</description>
        <time_frame>approximately 2 years and 2 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Treatment with TAC + MMF + corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Participants With HCV-positive and HCV Genotype</title>
          <description>The viral load of HCV-RNA and HCV genotype was assessed in HCV-positive patients.
The term &quot;genotype&quot; was used to describe strains of HCV that vary but were related to the virus. Worldwide, there were 11 primary groups of HCV genotypes designated by the numbers from 1-11, with the most common in our setting being subtypes 1a, 1b, 2 and 3, which were identified in the local laboratory according to their usual testing methods.</description>
          <population>ITT</population>
          <units>Percentages of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hepatitis C virus (HVC) positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33"/>
                    <measurement group_id="O2" value="36.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV genotype 01</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.00"/>
                    <measurement group_id="O2" value="76.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV genotype 02</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>HCV genotype 03</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.14"/>
                    <measurement group_id="O2" value="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV genotype 04</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86"/>
                    <measurement group_id="O2" value="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV genotype 05</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>HCV genotype 06</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>HCV genotype 07</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>non-responders</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of p-P70S6K</title>
        <description>the biomarker of personal response to everolimus, monitoring of the activity of the target, kinase P70 S6, in its phosphorylated form at Thr389.
EVR=everolimus Cmin=minimum concentration</description>
        <time_frame>weeks 6,8,12,18,24,36,52 at 0 (Cmin), and 1 (C1h) hrs post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of p-P70S6K</title>
          <description>the biomarker of personal response to everolimus, monitoring of the activity of the target, kinase P70 S6, in its phosphorylated form at Thr389.
EVR=everolimus Cmin=minimum concentration</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmin EVR week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1h EVR week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin EVR week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1h EVR week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin EVR week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1h EVR week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin EVR week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1h EVR week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin EVR week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1h EVR week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin EVR week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1h EVR week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin EVR week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.35" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1h EVR week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 2 years and 2 month.</time_frame>
      <desc>AE and SAE analyses were done on the safety population (N=215). The safety population included all randomised patients who had received at least one dose of the study medication. Patients were analysed according to the treatment received. All safety analyses were based on the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Experimental Group</title>
          <description>Minimisation of TAC: Treatment with rTAC+EVR+corticosteroids</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Treatment with TAC + MMF + corticosteroids.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Dieulafoy's vascular malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Localised intraabdominal fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Budd-Chiari syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Dilatation intrahepatic duct acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hepatic artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hepatic artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hepatic ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Liver transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pseudomonas bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Biliary anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Complications of transplanted liver</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Liver graft loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Transplant dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Endoscopic retrograde cholangiopancreatography</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Laboratory test</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of thorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device ineffective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Renal tubular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Testicular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Diaphragmatic paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bile duct stent removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Steal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cell death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

